There can be no assurance that the strategic review of Novartis India Limited will be completed in 2024, or that the outcome would result in the implementation of any transaction. Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years. Today Novartis proudly employs more than 8,100 associates in India.
Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 280 million people worldwide.Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 280 million people worldwide.
Novartis has had a significant footprint in India since 1947, with two legal entities namely, Novartis Healthcare Private Limited, and Novartis India Limited. India is amongst a handful of countries in the world that has a broad Novartis presence including Pharma International (commercial organization), Development (R&D organization), Novartis Corporate Center (Global Capability Center) and Biomedical Research. Employing nearly 8,100 people, Novartis India has consistently been recognised as a Top Employer.
Novartis India Limited is separate from Novartis Healthcare Private Limited, the wholly owned subsidiary of the Novartis group in India. Novartis Healthcare Private Limited includes the Novartis Corporate Center in Hyderabad, the commercial arm of Novartis in India, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country. The strategic review will not impact Novartis Healthcare Private Limited.